Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine 27Azacitidine 26venetoclax 23Cyclophosphamide 22Specimen Handling 21fludarabine phosphate 17Biopsy 16Whole-Body Irradiation 15Mycophenolic Acid 15Busulfan 15Melphalan 14Cytarabine 14Tacrolimus 13Granulocyte Colony-Stimulating Factor 12Decitabine 11Stem Cell Transplantation 10Injections 10Cyclosporine 10decitabine and cedazuridine drug combination 9Sirolimus 9Filgrastim 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7X-Rays 6Idarubicin 6ruxolitinib 5Cyclosporins 5Cladribine 5Methotrexate 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × seclidemstat × 90 days × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡